Digital Pharma: Boehringer’s bedtime stories

pharmafile | October 5, 2009 | Feature | Medical Communications |  Boehringer, digi, digital pharma, restless legs 

 

Boehringer Ingelheim has published an online book for European patients suffering from restless legs syndrome.

The educational resource, which is available at rlsbookofbedtimestories.com, was launched from the company’s European head office and contains short case studies of patients Sue (UK), John (UK), Silvana (Italy) and Hans (Germany).

The short 25-page volume offers information on the symptoms of RLS, lifestyle advice for managing them when mild or intermittent and notes that approved and effective RLS treatments are available.

It also includes a forward from Olympic track and field competitor and restless legs syndrome (RLS) patient Zola Budd-Pieterse.

Advertisement

It’s not Boehringer’s first online patient information effort. The company runs a German patient site for RSL and earlier this year launched the rlsunderthecovers.com website.

Boehringer markets RLS treatment pramipexole in Europe under the brand names Mirapexin and Sifrol, and is currently seeking approval for a new, once-daily prolonged-release formulation.

Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog. He can be contacted via email, Twitter or LinkedIn.

Blog footer

Related Content

heart-2372134_640

Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 …

shutterstock_138095450

Boehringer withdraws its £700m investment in Hikma Pharmaceuticals

Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the …

boehringer_biberach_germany_copy

Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype

The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment …

The Gateway to Local Adoption Series

Latest content